The Kitasato Institute
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
1
Ending by 2030
Jan 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Method for producing mycosporine-like amino acid using microbes (US 10,307,356) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Feb 11, 2027The maintenance fee for Therapeutic agent and therapeutic device for alleviating ischemia-reperfusion injury (US 9,101,556) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,519,128 | Pyripyropene derivatives having an ACAT2-inhibiting activity In force · USPTO record | In force | USPTO record | |
| US 9,101,556 | Therapeutic agent and therapeutic device for alleviating ischemia-reperfusion injury In force · USPTO record | In force | USPTO record | |
| US 9,526,765 | Delivery of Therapeutic Agents by a Collagen Binding Protein In force · High confidence | In force | High confidence | |
| US 11,279,922 | Delivery of Therapeutic Agents by a Collagen Binding Protein In force · High confidence | In force | High confidence | |
| US 10,213,488 | Delivery of Therapeutic Agents by a Collagen Binding Protein In force · High confidence | In force | High confidence | |
| US 10,307,356 | Method for producing mycosporine-like amino acid using microbes In force · USPTO record | In force | USPTO record | |
| US 10,202,627 | Method for Producing Trehangelin In force · High confidence | In force | High confidence | |
| US 11,407,742 | Compound having therapeutic activity against mycobacterium avium complex infection, and method for producing same In force · USPTO record | In force | USPTO record | |
| US 11,517,616 | Composite Polypeptide Monomer, Aggregate of Said Composite Polypeptide Monomer Having Cell Penetration Function, and Norovirus Component Vaccine for Subcutaneous, Intradermal, Percutaneous, or Intramuscular Administration and Having Said Aggregate as Effective Component Thereof In force · High confidence | In force | High confidence | |
| US 12,239,619 | Composition for inducing pili formation in bacterium of genus Bifidobacterium In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 13: 12 patents in force now held by others · 40 lapsed for an unpaid fee · 46 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 5 abandoned · 16 no status recorded